Gemphire Therapeutics Profile

USD 0.17  7.66%

Exercise or conversion by Jeffrey Mathiesen of 3000 shares of Gemphire Therapeutics subject to Rule 16b-3

Gemphire Therapeutics insider trading alert for exercise of employee stock option (right to buy) by Jeffrey Mathiesen, Chief Financial Officer, on July 25, 2018. This event was filed by Gemphire Therapeutics Inc with SEC on 2017-08-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Gemphire Therapeutics Summary

Gemphire Therapeutics (GEMP) is traded on BATS Exchange in USA. It is located in MICHIGAN U.S.A and employs 17 people. Gemphire Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 34.09 M. Gemphire Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. This company has 14.27 M outstanding shares of which 867.16 K shares are currently shorted by private and institutional investors with about 0.68 trading days to cover. Gemphire Therapeutics Inc. currently holds about 28.04 M in cash with (27.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.97.
Check Gemphire Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Gemphire Therapeutics Target Price Odds Analysis

Odds Below 2.39HorizonTargetOdds Above 2.39
89.68%30 days 2.39 10.27%
Based on normal probability distribution, the odds of Gemphire Therapeutics to move above current price in 30 days from now is about 10.27% (This Gemphire Therapeutics probability density function shows the probability of Gemphire Therapeutics Stock to fall within a particular range of prices over 30 days) .

Gemphire Therapeutics Top Holders

Gemphire Therapeutics Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Cormorant Asset Management LpCommon Shares1 M10.6 M
Northpointe Capital LlcCommon Shares698.8 K7.1 M
View Gemphire Therapeutics Diagnostics

Gemphire Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Gemphire Therapeutics Key Fundamentals

Gemphire Therapeutics Against Markets

Gemphire Therapeutics Current Ratings

Gemphire Therapeutics 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Gemphire Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis . The company was founded in 2008 and is headquartered in Livonia, Michigan. Gemphire Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 17 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gemphire Therapeutics SEC Filings
Gemphire Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGemphire Therapeutics
President CEOMina SoochView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
Business Address17199 North Laurel Park Drive
ExchangeBATS Exchange
Phone734 245 1700
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 31, 2018

Gemphire Therapeutics Directors

Gemphire Therapeutics Corporate Directors

Kenneth Kousky Independent Director
Andrew Sassine Independent Director
Pedro Lichtinger Independent Director
Please also check Risk vs Return Analysis. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.